Highly Galactosylated Anti-ACVR2B (Bimagrumab) Antibody (CAT#: BioBet-GA-060ZP) Datasheet

ACVR2B

Activin A Receptor Type 2B

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. [provided by RefSeq, Jul 2008]

Bimagrumab; 1356922-05-8; BYM338; BYM338; ACVR2B; activin A receptor, type IIB; activin receptor type-2B; ActR IIB; HTX4; ACTRIIB; ActR-IIB;

Plasma membrane

Its related pathways are Signaling by NODAL and Signaling by GPCR.

The transmembrane serine/threonine kinase activator protein type 2 receptor and the activin type 1 serine/threonine kinase receptor (ACVR1, ACVR1B or ACVR1c) form an activator protein receptor complex. It can sense activin signals from the cell surface to the cytoplasm, thus regulating many physiological and pathological processes including neuron differentiation and neuron survival, hair follicle development and circulation, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression And carcinogenic effects. Activin is also believed to have a paracrine or autocrine effect in the development of ovarian follicles. In the receptor complex, type 2 receptors are the main activin receptors (binding activin-a /INHBA, activin-b /INHBB and inhibitory protein-a /INHA-INHBA). Type 1 receptors such as ACVR1B act as downstream transducers of activin signals. The activator protein binds to the type 2 receptor on the plasma membrane and activates its serine-threonine kinase. The activated type 2 receptor then phosphorylates and activates the type 1 receptor. Once activated, type 1 receptors bind to and phosphorylate the SMAD proteins SMAD2 and SMAD3 at the c-terminal serine residue. Shortly after SMAD2 and SMAD3 bind to the activin receptor and are subsequently phosphorylated, they are released into the cytoplasm and interact with their common partner SMAD4. This SMAD complex is transferred to the nucleus, where it mediates activity-induced transcription. Inhibition of SMAD7 being recruited to ACVR1B through FKBP1A can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking activin signaling. Activin signal transduction is also antagonized by the binding of the IGSF1 inhibin co-receptor to the inhibin-b receptor.

1.Phosphorylated. Constitutive phosphorylation is in part catalyzed by its own kinase activity. 2.Glycosylation at Asn42 and Asn65 3.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1, λ

Bimagrumab

Human

Human

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human ACVR2B. Bimagrumab is a human monoclonal antibody developed to treat pathological muscle loss and weakness.

Cachexia

Cachexia